Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium

This study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal injury or Multiple Sclerosis (MS) who are prescribed BOTOX® as standard of care in clinical practice.

Inclusion Criteria:

• Patients prescribed BOTOX® for urine incontinence from NDO due to spinal injury or MS as standard of care in clinical practice in Belgium
• Previous treatment with anticholinergic drugs ineffective
• Last BOTOX® treatment ≥18 months.

Exclusion Criteria:

• Diagnosis of urinary incontinence less than 9 months.
• No anticholinergic drug use in the last 9 months.